Petros Pharmaceuticals (PTPI) Competitors $0.02 0.00 (-2.97%) As of 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. ARTL, PRFX, CERO, GTBP, PWUP, VCNX, GLMD, SPRC, SLRX, and PTIXShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Artelo Biosciences (ARTL), PainReform (PRFX), CERo Therapeutics (CERO), GT Biopharma (GTBP), PowerUp Acquisition (PWUP), Vaccinex (VCNX), Galmed Pharmaceuticals (GLMD), SciSparc (SPRC), Salarius Pharmaceuticals (SLRX), and Atrinsic (PTIX). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Artelo Biosciences PainReform CERo Therapeutics GT Biopharma PowerUp Acquisition Vaccinex Galmed Pharmaceuticals SciSparc Salarius Pharmaceuticals Atrinsic Petros Pharmaceuticals (NASDAQ:PTPI) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership. Do insiders & institutionals hold more shares of PTPI or ARTL? 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor PTPI or ARTL? In the previous week, Artelo Biosciences had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.50 indicating that Petros Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Petros Pharmaceuticals Neutral Artelo Biosciences Negative Which has more volatility & risk, PTPI or ARTL? Petros Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Is PTPI or ARTL more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Artelo Biosciences N/A -497.68%-213.76% Do analysts prefer PTPI or ARTL? Artelo Biosciences has a consensus price target of $24.00, suggesting a potential upside of 610.06%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Which has better valuation & earnings, PTPI or ARTL? Petros Pharmaceuticals has higher revenue and earnings than Artelo Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.12-$8.16M-$52.910.00Artelo BiosciencesN/AN/A-$9.83M-$19.05-0.18 SummaryPetros Pharmaceuticals beats Artelo Biosciences on 9 of the 15 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$629K$1.03B$6.18B$10.67BDividend YieldN/A4.84%5.72%4.86%P/E Ratio0.001.2629.0927.12Price / Sales0.1230.41584.14126.40Price / CashN/A17.6337.1261.42Price / Book0.007.7812.246.43Net Income-$8.16M-$8.09M$3.33B$276.63M7 Day PerformanceN/A2.04%-1.46%-2.60%1 Month PerformanceN/A26.01%5.03%0.31%1 Year PerformanceN/A-14.40%61.45%30.63% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros PharmaceuticalsN/A$0.02-3.0%N/A-99.8%$629K$5.11M0.0020Gap DownARTLArtelo Biosciences2.2196 of 5 stars$3.65-6.1%$24.00+558.4%-53.6%$2.55MN/A-0.195Short Interest ↑PRFXPainReform0.9653 of 5 stars$1.27-1.9%N/A-56.8%$2.54MN/A-0.014CEROCERo Therapeutics3.5892 of 5 stars$2.07-13.8%$45.00+2,073.9%-98.8%$2.53MN/A0.008News CoverageAnalyst ForecastShort Interest ↓Gap UpGTBPGT Biopharma2.0004 of 5 stars$0.70-3.8%$11.00+1,467.0%-71.1%$2.50MN/A-0.178PWUPPowerUp AcquisitionN/A$0.32-7.5%N/A-97.6%$2.45MN/A0.00N/AGap DownHigh Trading VolumeVCNXVaccinex0.8625 of 5 stars$0.91-5.7%N/A-66.0%$2.38M$388K-0.0240News CoverageGap DownGLMDGalmed Pharmaceuticals2.2817 of 5 stars$1.44+1.4%N/A-69.4%$2.38MN/A-0.0920Positive NewsSPRCSciSparc0.4104 of 5 stars$4.26-1.2%N/A-30.2%$2.28M$1.31M0.004SLRXSalarius Pharmaceuticals0.1742 of 5 stars$3.81-5.9%N/A-86.2%$1.94MN/A-0.0920Negative NewsShort Interest ↑PTIXAtrinsic0.2033 of 5 stars$3.16-1.6%N/A-68.2%$1.86MN/A-0.332 Related Companies and Tools Related Companies Artelo Biosciences Competitors PainReform Competitors CERo Therapeutics Competitors GT Biopharma Competitors PowerUp Acquisition Competitors Vaccinex Competitors Galmed Pharmaceuticals Competitors SciSparc Competitors Salarius Pharmaceuticals Competitors Atrinsic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredBitcoin is dead?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts